Ultragenyx Pharmaceutical Inc.RARE stock score: 47/100
$17.22 · -2.88% · Scored Nov 19, 2026
- Technical
- 36
- Fundamental
- 49
- News
- —
The reading
Ultragenyx Pharmaceutical (RARE) scores 47 out of 100, which reads weak, higher than 39% of Healthcare stocks and 37% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 49, technicals 36.
Among the fundamentals, Price Target at 100 and Revenue Growth (Annual) at 97 score highest, while Earnings Profitability (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 52 and contrarian oscillators 36.
Since Aug 22, 2026 the composite has ranged from 31 to 47, and it is up 9 points over the period.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical (RARE) is a biopharmaceutical company that develops and sells treatments for rare and ultra-rare genetic diseases. Its commercial products include Crysvita, an antibody for X-linked hypophosphatemia developed with Kyowa Kirin, Dojolvi for long-chain fatty acid oxidation disorders, and Mepsevii, an enzyme replacement therapy for MPS VII. It also sells Evkeeza outside the United States under an agreement with Regeneron. Its gene therapy Fayuvi, also known as UX111, is approved in the United States for Sanfilippo syndrome type A, and its gene therapy DTX401, sold as Genglycos, has received accelerated approval for glycogen storage disease type Ia. The company is also developing GTX-102 for Angelman syndrome. Ultragenyx earns money from product sales, from its share of Crysvita profits and royalties, and from sales of priority review vouchers.
Ultragenyx competes with other rare disease drugmakers such as BioMarin Pharmaceutical, with Ionis Pharmaceuticals in Angelman syndrome and with gene therapy developers. Its edge rests on experience running trials in very small patient groups, its own gene therapy manufacturing and a commercial team that reaches rare disease specialists worldwide. Investors who follow RARE stock tend to watch Crysvita and Dojolvi sales and the launches of its gene therapies. Results and regulatory progress for GTX-102 are closely followed. Operating expenses, cash runway and progress toward profitability are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward RARE’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
49Pulling it up
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Annual revenue growth tracks year-over-year sales expansion.
Forward P/E ratio uses estimated future earnings to calculate valuation.
Holding it back
Earnings Profitability (Quarterly) measures recent profitability using trailing 12-month quarterly data.
Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.
5-year earnings growth evaluates long-term profit trajectory and consistency.
36 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical · daily
45Pulling it up
Performance versus SPY compares the stock's returns to the S&P 500 index.
- VWAP98
Volume Weighted Average Price (VWAP) shows the average price weighted by volume.
- SMA 591
Simple Moving Average (5-period) tracks the average price over the last 5 periods.
Holding it back
S&P 500 52-week comparison evaluates the stock's annual performance relative to the broader market.
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Where the close sits against its 200-day SMA.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 51 | 1 |
| Daily | 45 | 3 |
| Weekly | 25 | 2 |
| Monthly | 26 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 47 |
| Nov 18, 2026 | 47 |
| Nov 17, 2026 | 46 |
| Nov 16, 2026 | 45 |
| Nov 15, 2026 | 45 |
| Nov 14, 2026 | 45 |
| Nov 13, 2026 | 45 |
| Nov 12, 2026 | 44 |
| Nov 11, 2026 | 37 |
| Nov 10, 2026 | 35 |
| Nov 8, 2026 | 32 |
| Nov 7, 2026 | 32 |
| Nov 6, 2026 | 32 |
| Nov 5, 2026 | 33 |
| Nov 4, 2026 | 37 |
| Nov 3, 2026 | 34 |
| Nov 2, 2026 | 35 |
| Nov 1, 2026 | 34 |
| Oct 31, 2026 | 34 |
| Oct 30, 2026 | 34 |
| Oct 29, 2026 | 36 |
| Oct 28, 2026 | 36 |
| Oct 27, 2026 | 36 |
| Oct 26, 2026 | 35 |
| Oct 25, 2026 | 34 |
| Oct 24, 2026 | 34 |
| Oct 23, 2026 | 34 |
| Oct 22, 2026 | 35 |
| Oct 21, 2026 | 35 |
| Oct 20, 2026 | 35 |
| Oct 19, 2026 | 34 |
| Oct 18, 2026 | 33 |
| Oct 17, 2026 | 33 |
| Oct 16, 2026 | 33 |
| Oct 15, 2026 | 35 |
| Oct 14, 2026 | 34 |
| Oct 13, 2026 | 34 |
| Oct 12, 2026 | 36 |
| Oct 11, 2026 | 36 |
| Oct 10, 2026 | 36 |
| Oct 9, 2026 | 36 |
| Oct 8, 2026 | 36 |
| Oct 7, 2026 | 36 |
| Oct 6, 2026 | 34 |
| Oct 5, 2026 | 34 |
| Oct 4, 2026 | 35 |
| Oct 3, 2026 | 35 |
| Oct 2, 2026 | 36 |
| Oct 1, 2026 | 34 |
| Sep 30, 2026 | 35 |
| Sep 29, 2026 | 35 |
| Sep 28, 2026 | 34 |
| Sep 27, 2026 | 34 |
| Sep 26, 2026 | 34 |
| Sep 25, 2026 | 33 |
| Sep 24, 2026 | 34 |
| Sep 23, 2026 | 34 |
| Sep 22, 2026 | 35 |
| Sep 21, 2026 | 34 |
| Sep 20, 2026 | 34 |
| Sep 19, 2026 | 33 |
| Sep 18, 2026 | 33 |
| Sep 17, 2026 | 33 |
| Sep 16, 2026 | 31 |
| Sep 15, 2026 | 31 |
| Sep 14, 2026 | 31 |
| Sep 13, 2026 | 32 |
| Sep 12, 2026 | 32 |
| Sep 11, 2026 | 32 |
| Sep 10, 2026 | 32 |
| Sep 9, 2026 | 32 |
| Sep 8, 2026 | 32 |
| Sep 7, 2026 | 32 |
| Sep 6, 2026 | 32 |
| Sep 5, 2026 | 32 |
| Sep 4, 2026 | 32 |
| Sep 3, 2026 | 36 |
| Sep 2, 2026 | 34 |
| Sep 1, 2026 | 39 |
| Aug 31, 2026 | 36 |
| Aug 30, 2026 | 38 |
| Aug 29, 2026 | 38 |
| Aug 28, 2026 | 37 |
| Aug 27, 2026 | 39 |
| Aug 26, 2026 | 39 |
| Aug 25, 2026 | 40 |
| Aug 24, 2026 | 37 |
| Aug 23, 2026 | 38 |
| Aug 22, 2026 | 38 |
Key facts
- Market cap
- $1.8B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 0.36
- Risk grade (1–10)
- 6
- Next earnings
- Nov 3, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| REPL Replimune Group | $1.8B | 41 |
| MAZE Maze Therapeutics | $1.8B | 34 |
| STOK Stoke Therapeutics | $1.8B | 52 |
| AGIO Agios Pharmaceuticals | $1.7B | 47 |
| ZBIO Zenas BioPharma | $1.7B | 31 |
| RXRX Recursion Pharmaceuticals | $1.7B | 45 |
Questions
What is RARE's stock rating today?
RARE scores 47/100 (Weak) as of Nov 19, 2026: technical 36, fundamental 49. Scores are recomputed every night.
What does Ultragenyx Pharmaceutical do?
Ultragenyx Pharmaceutical (RARE) is a biopharmaceutical company that develops and sells treatments for rare and ultra-rare genetic diseases. Its commercial products include Crysvita, an antibody for X-linked hypophosphatemia developed with Kyowa Kirin, Dojolvi for long-chain fatty acid oxidation disorders, and Mepsevii, an enzyme replacement therapy for MPS VII.
Is RARE stock a buy?
The score is not a buy or sell recommendation. A 47 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the RARE score calculated?
98 weighted scorers feed it today: 36 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/rare/"><img src="https://stocksscores.com/stocks/rare/badge.svg" alt="RARE stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/rare/)